Clinical Trials
41 trialsNF114
University of Alabama at Birmingham
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
Sarcoma Alliance for Research through Collaboration
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Selumetinib and Olaparib in Solid Tumors
M.D. Anderson Cancer Center
NF113
University of Alabama at Birmingham
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
University of Alabama at Birmingham
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
University Health Network, Toronto
Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
MEKMDM2
Children's National Research Institute
SEL-TH-1601
Children's Hospital Medical Center, Cincinnati
SAFIR02_Breast
UNICANCER
LS-NF1PNs
West China Hospital
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
DOC-MEK
University of Oxford
Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Academic and Community Cancer Research United
INSPECT
Great Ormond Street Hospital for Children NHS Foundation Trust
SAFIR02_Lung
UNICANCER
Intermittent Selumetinib for Uveal Melanoma
Columbia University
SeluDex
University of Birmingham
DREAMtherapy
The Christie NHS Foundation Trust
Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
OHSU Knight Cancer Institute
MEKRT
The Christie NHS Foundation Trust
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
Cancer Research UK
Personalized Treatment Selection for Metastatic Breast Cancer
M.D. Anderson Cancer Center
TORCMEK
Queen Mary University of London
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
Swiss Cancer Institute
SCART
Sheffield Teaching Hospitals NHS Foundation Trust
M14AFS
The Netherlands Cancer Institute
Selumetinib in Combination With Gefitinib in NSCLC Patients
National Taiwan University Hospital
MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)
M.D. Anderson Cancer Center
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Memorial Sloan Kettering Cancer Center
Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer
University of Miami
ABC-04
University College, London
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Russian Academy of Medical Sciences
AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma
National Cancer Centre, Singapore